The activity of VIP-E SDC and VIC-E HDC is not superior to that of established protocols in the treatment of NSCLC. In view of the toxicity and TRM associated with this protocol, less aggressive regimens should be preferred for most patients. Whether selected patients with chemosensitive disease could benefit from VIP-E SDC and/or VIC-E HDC in an adjuvant or neo-adjuvant setting could not be determined within the scope of this study.
SummaryBackground: We conducted a phase I/II trial to assess the feasibility and activity of combination chemotherapy with etoposide, ifosfamide, cisplatin, and epinibicin in limited-stage (LS, stage I-IIIB) and extensive-stage (ES, stage IV) non-smallcell lung cancer (NSCLQ. End-points were treatment-related morbidity and mortality, response rate, duration of response, and survival.Patients and methods: Chemotherapy followed by granulocyte colony-stimulating factor was given at a dose of etoposide (500 mg/m 2 ), ifosfamide (4000 mg/m 2 ), cisplatin (50 mg/m 2 ), and epirubicin (50 mg/m 2 ) (VIP-E) to 107 patients with NSCLC. Twenty-five patients with qualifying responses proceeded to high-dose chemotherapy with autologous peripheral blood stem cell transplantation after etoposide (1500 mg/m 2 ), ifosfamide (12,000 mg/m 2 ), carboplatin (750 mg/m 2 ) and epirubicin (150 mg/m 2 ) (VIC-E) conditioning.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.